Stockscreener 앱 받기
74.84
2.27%
1.66
시간 외 거래:
74.84
전일 마감가:
$73.18
열려 있는:
$73.05
하루 거래량:
571.76K
Relative Volume:
0.50
시가총액:
$2.09B
수익:
$55.23M
순이익/손실:
$-164.08M
주가수익비율:
-10.93
EPS:
-6.8461
순현금흐름:
$-208.68M
1주 성능:
+6.37%
1개월 성능:
+1.33%
6개월 성능:
+35.73%
1년 성능:
+8,242%
1일 변동 폭
$71.64
$76.65
1주일 범위
$70.00
$77.00
52주 변동 폭
$0.432
$77.00
넥타테라퓨틱스 Stock (NKTR) Company Profile
명칭
Nektar Therapeutics
전화
(415) 482-5300
주소
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
74.84 | 2.05B | 55.23M | -164.08M | -208.68M | -6.8461 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
넥타테라퓨틱스 Stock (NKTR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-17 | 개시 | TD Cowen | Buy |
| 2026-02-10 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-11-26 | 개시 | Citigroup | Buy |
| 2025-06-24 | 재확인 | BTIG Research | Buy |
| 2025-06-24 | 재확인 | H.C. Wainwright | Buy |
| 2025-04-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-03-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-01-08 | 개시 | B. Riley Securities | Buy |
| 2024-12-10 | 개시 | H.C. Wainwright | Buy |
| 2024-11-04 | 개시 | Piper Sandler | Overweight |
| 2024-09-30 | 재개 | BTIG Research | Buy |
| 2024-06-28 | 개시 | Rodman & Renshaw | Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-11-09 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-02-24 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2022-08-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-31 | 재개 | Jefferies | Hold |
| 2022-04-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-03-15 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-08 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-09-10 | 개시 | BofA Securities | Neutral |
| 2021-06-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-02-22 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-09-14 | 개시 | JP Morgan | Neutral |
| 2020-06-10 | 다운그레이드 | CFRA | Hold → Sell |
| 2020-05-12 | 재확인 | H.C. Wainwright | Neutral |
| 2020-04-22 | 개시 | The Benchmark Company | Buy |
| 2020-03-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-08 | 다운그레이드 | Goldman | Buy → Sell |
| 2019-08-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-08-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-03-15 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-06-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | 재확인 | H.C. Wainwright | Buy |
| 2018-04-20 | 개시 | Seaport Global Securities | Buy |
| 2018-04-13 | 재개 | Piper Jaffray | Overweight |
| 2018-04-06 | 재확인 | Mizuho | Buy |
| 2018-04-02 | 재개 | H.C. Wainwright | Buy |
모두보기
넥타테라퓨틱스 주식(NKTR)의 최신 뉴스
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain OfficersNKTR - PR Newswire
Portnoy Law Firm Announces Class Action on Behalf of Nektar Therapeutics, Inc. Investors - GlobeNewswire
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein - GlobeNewswire
NKTR Investor Alert: Nektar Therapeutics Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: Levi & Korsinsky - PR Newswire
Holzer & Holzer, LLC Reminds Investors of May 5, 2026 Lead - GlobeNewswire
Holzer & Holzer, LLC Reminds Investors of May 5, 2026 Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Nektar Therapeutics (NKTR) and Eos Energy Enterprises, Inc. (EOSE) - GlobeNewswire Inc.
Nektar Therapeutics (NKTR) Receives New 'Buy' Rating from TD Cowen | NKTR Stock News - GuruFocus
Should Mixed Q4 Results and REZOLVE-AA Lawsuits Reshape Nektar Therapeutics’ (NKTR) Rezpegaldesleukin-Focused Strategy? - simplywall.st
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics - GlobeNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
NKTR Shareholder Alert: May 5, 2026 Lead Plaintiff Deadline in Nektar Therapeutics Securities Class Action Lawsuit -- The Gross Law Firm - PR Newswire
Nektar Therapeutics (NASDAQ:NKTR) Coverage Initiated at TD Cowen - MarketBeat
Nektar Therapeutics stock initiated with buy rating at TD Cowen By Investing.com - Investing.com India
H.C. Wainwright Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $165 - 富途牛牛
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Nektar Therapeutics stock initiated with buy rating at TD Cowen - Investing.com
TD Cowen Starts Nektar Therapeutics (NKTR) at Buy - StreetInsider
Rosen Law Firm Encourages Nektar Therapeutics Investors to Secure Counsel Before Deadline - National Today
Nektar Therapeutics (NKTR) Analyst Rating Update: Citigroup Rais - GuruFocus
Nektar Therapeutics (NASDAQ:NKTR) Price Target Raised to $123.00 at Citigroup - MarketBeat
Law Offices of Frank R. Cruz Encourages Nektar Therapeutics (NKTR) Shareholders To Inquire About Securities Fraud Class Action - The AI Journal
Wall Street experts project a potential 77.28% increase for Nektar (NKTR): Is such a surge in the stock truly achievable? - Bitget
NKTR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Citi Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Raises Target Price to $123 - 富途牛牛
Farallon Capital Management LLC Invests $45.01 Million in Nektar Therapeutics $NKTR - MarketBeat
NKTR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Nektar Q4 earnings & revenues trump estimates, pipeline in focus - MSN
NKTR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 (2026-03-15) - Seeking Alpha
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit - The Norfolk Daily News
Nektar Therapeutics (NASDAQ:NKTR) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
22NW LP Increases Stock Holdings in Nektar Therapeutics $NKTR - MarketBeat
A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Momentum And Undervaluation Signals - simplywall.st
Analysts Offer Insights on Healthcare Companies: Agilent (A), Natera (NTRA) and Nektar Therapeutics (NKTR) - The Globe and Mail
NKTR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Nektar - GlobeNewswire
Quinn Opportunity Partners LLC Purchases Shares of 109,868 Nektar Therapeutics $NKTR - MarketBeat
Nektar Therapeutics stock hits 52-week high at 76.3 USD By Investing.com - Investing.com South Africa
Decoding Nektar Therapeutics (NKTR): A Strategic SWOT Insight - GuruFocus
Nektar Therapeutics jumps on Q4 results - MSN
Nektar Therapeutics Bets Big on Respag Phase 3 - TipRanks
Nektar Therapeutics (NKTR) Q3 Losses Narrow To US$35.5 Million Testing Bearish Narratives - simplywall.st
Oppenheimer Maintains Outperform on Nektar Therapeutics (NKTR) March 2026 - Meyka
Class Action Lawsuit Announced for Nektar Therapeutics - Intellectia AI
Nektar outlines $400M–$460M year-end 2026 cash target as REZPEG enters phase III in atopic dermatitis - MSN
Oppenheimer raises Nektar Therapeutics price target to $140 By Investing.com - Investing.com Australia
ROSEN, A HIGHLY RANKED LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, A HIGHLY RANKED LAW FIRM, Encourages Nektar - GlobeNewswire
Oppenheimer raises Nektar Therapeutics price target to $140 - Investing.com India
NKTR (NASDAQ) director sells proposed 78,510 shares via Fidelity - Stock Titan
Nektar Therapeutics (NKTR) PT Raised to $140 at Oppenheimer - StreetInsider
Nektar Therapeutics stock hits 52-week high at 76.3 USD - Investing.com Nigeria
Nektar Q4 Earnings & Revenues Trump Estimates, Pipeline in Focus - Yahoo Finance
넥타테라퓨틱스 (NKTR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):